Literature DB >> 26459365

Bone Marrow Edema Syndrome of the Foot and Ankle: Mid- to Long-Term Follow-up in 18 Patients.

Dishan Singh1, Andrea Ferrero2, Barry Rose2, Andrew Goldberg2, Nicholas Cullen2.   

Abstract

UNLABELLED: Bone marrow edema syndrome (BMES) is a condition characterized by pain and an increase interstitial fluid within the bone marrow in the absence of a definable cause. The purpose of this study was to assess the changes in the pattern of bone edema and quality of pain over time. In patients diagnosed with BMES of the foot and ankle, we investigated the benefit of treatment with bisphosphonates and immobilization in a pneumatic walking boot compared with immobilization in a boot alone. This study is a retrospective review of 18 consecutive patients (mean age 54 years) diagnosed with foot and ankle BMES. Twelve (67%) patients were female and 6 were male with a mean age of 60.1 and 43.0 years, respectively (P < .05). The minimum follow-up was 2 years (range 2-11 years, mean 5.75 years). Five females and no males were found to suffer from generalized osteoporosis. The average duration of symptoms prior to presentation was 22 weeks and the most common bone affected was the talus (56%). More than one bone was affected in 8 (44%) patients. All patients were given a walking boot at first attendance for 8 weeks. The mean time to resolution of pain in patients treated with a pneumatic walker alone (7 patients) was 25.6 weeks (range 8-36 weeks). In the 11 patients whose pain had not improved at their first follow-up, treatment with bisphosphonates led to a more rapid resolution of pain in 13.8 weeks if given intravenously, and 24.0 weeks if given orally. Statistical analysis demonstrated a significant advantage in using a bisphosphonate versus a protected weightbearing alone (P < .01). Recurrence within the same foot and ankle occurred in 44% of patients at a mean interval of 15.6 months and migration to a different site occurred in 6% of patients. LEVELS OF EVIDENCE: Therapeutic, Level III: Retrospective, comparative trial.
© 2015 The Author(s).

Entities:  

Keywords:  bisphosphonates; bone marrow edema syndrome; chronic regional pain syndrome; regional migratory osteoporosis; transient osteoporosis

Mesh:

Substances:

Year:  2015        PMID: 26459365     DOI: 10.1177/1938640015609986

Source DB:  PubMed          Journal:  Foot Ankle Spec        ISSN: 1938-6400


  6 in total

1.  Zoledronic acid in nine patients with transient osteoporosis of the hip.

Authors:  Gerasimos Evangelatos; George E Fragoulis; Alexios Iliopoulos
Journal:  Clin Rheumatol       Date:  2019-11-23       Impact factor: 2.980

Review 2.  The efficacy and safety of bisphosphonates in patients with bone marrow edema syndrome/transient osteoporosis: A systematic literature review.

Authors:  Athanasios N Ververidis; Konstantinos Paraskevopoulos; Anthimos Keskinis; Georgios I Petkidis; Konstantinos Tilkeridis
Journal:  J Orthop       Date:  2020-11-19

3.  Bone marrow oedema syndrome of the foot and ankle in a paediatric population: a retrospective case series with serial MRI evaluation.

Authors:  Hannah De Houwer; Nathalie Van Beek; Sandra Prinsen; Anne Van Riet; Jeoffrey De Roeck; Stefaan Verfaillie
Journal:  J Child Orthop       Date:  2020-10-01       Impact factor: 1.548

4.  Risk factors in transient osteoporosis: a retrospective study on 23 cases.

Authors:  Carlo Trevisan; Raymond Klumpp; Riccardo Compagnoni
Journal:  Clin Rheumatol       Date:  2016-03-16       Impact factor: 2.980

5.  Zoledronic acid is effective in the management of migratory osteoporosis unresponsive to conservative treatment and risedronate: A case report.

Authors:  Gerasimos Evangelatos; George E Fragoulis; Athanasios D Anastasilakis; Alexios Iliopoulos
Journal:  J Musculoskelet Neuronal Interact       Date:  2021-03-01       Impact factor: 2.041

6.  Is Primary Bone Marrow Edema of the Knee Associated with Thyroid Disorders? A Retrospective Clinical Study.

Authors:  Luca De Berardinis; Fjorela Qordja; Luca Farinelli; Andrea Faragalli; Rosaria Gesuita; Antonio Pompilio Gigante
Journal:  J Clin Med       Date:  2022-10-10       Impact factor: 4.964

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.